Inmune Bio (0Y2) Price & Analysis

0 Followers

0Y2 Stock Chart & Stats

€1.39

€0.00(0.00%)

At close: Jul 27 4:00 PM EDT

€1.39

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€1.21 - €1.95

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€58.80M

Enterprise Value€26.55

Total Cash (Recent Filing)€18.41M

Total Debt (Recent Filing)€1.41M

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Nov 04, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.69

Shares Outstanding27,753,790

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)1.76

Price to Sales (P/S)829.46

P/FCF Ratio-1.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€6.87

Price Target Upside394.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.52

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory PathwayFormal MHRA alignment and a defined sequence of UK, European and U.S. submissions reduce regulatory uncertainty around Ebstracel. The pediatric investigation plan was approved in under three months, creating a clearer development pathway and several durable execution milestones.

Manufacturing ReadinessProgress toward commercial-compliant processing and transfer of the MSC isolation stage indicates that manufacturing preparations are advancing beyond early research. Expanded access to qualified cord tissue supports regulatory submissions and could improve readiness for future commercial supply.

XPro Clinical ProgressFast Track designation and statistically significant Phase 2 imaging results strengthen XPro's development profile in Alzheimer's disease. The biomarker-enriched effect may help guide patient selection and supports continued clinical advancement, although confirmatory evidence remains necessary.

Bears Say

No Commercial RevenueINMB remains pre-commercial, so its programs have not yet produced an operating revenue base to offset research and development costs. Continued losses leave financial performance dependent on clinical progress, regulatory success and access to external capital rather than recurring product sales.

Cash Runway And DilutionThe projected runway supports near-term milestones but does not cover the company's longer development and commercialization needs. Future financing may therefore be required, and equity funding could dilute existing holders while competing with clinical and regulatory spending for available capital.

Confirmatory Trial TimingThe confirmatory trial's extended duration and controlled enrollment pace could delay full evidence supporting approval and commercial adoption. A longer path to definitive data leaves the company exposed to execution risk and prolongs the period before the program can generate dependable product revenue.

Inmune Bio News

INmune Bio submits two regulatory packages to EMA for Ebstrocel

INmune Bio (INMB) announced that it has submitted two regulatory packages to the European Medicines Agency, or EMA,...

16d ago

INMB

INmune Bio Earnings Call Highlights De-Risking, Cash Risks

Inmune Bio (($INMB)) has held its Q2 earnings call. Read on for the main highlights of the call....

19d ago

INMB

Jason McCarthy Reiterates Buy on INmune Bio, Keeps $8 Price Target Amid Advancing Clinical and Regulatory Milestones

Maxim Group analyst Jason McCarthy maintained a Buy rating on Inmune Bio on August 11 and set a...

29d ago

INMB

INmune Bio Strengthens Cash Runway With R&D Rebates

Inmune Bio ( ($INMB) ) just unveiled an announcement. On July 30, 2026, INmune Bio received an R&D...

1M ago

INMB

INmune Bio receives $4.6M in rebates from Australia, UK

INmune Bio (INMB) announced that on July 30, it received a research and development cash rebate from Australia...

1M ago

INMB

INmune Bio processes first umbilical cord tissue at CGT Catapult

INmune Bio (INMB) announced the company has successfully processed its first commercial-ready umbilical cord tissue at the Cell...

2M ago

INMB

Strengthening XPro1595 Data and De-Risked Registrational Path Support Buy Rating on INmune Bio with Unchanged $8 Price Target

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio, retaining the price target of...

2M ago

INMB

INmune Bio Executes Warrant Inducement and Extension Agreement

Inmune Bio ( ($INMB) ) has provided an announcement. On June 30, 2026, INmune Bio entered into a...

2M ago

INMB

INmune Bio advances CORDStrom platform patent application in the U.S.

INmune Bio (INMB) announced that it has submitted its CORDStrom platform patent application into the U.S. national phase...

2M ago

INMB

INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan

INmune Bio (INMB) announced that the UK Medicines & Healthcare products Regulatory Agency, or MHRA, has approved the...

3M ago

INMB

INmune Bio Advances Ebstrocel Toward UK Conditional Approval

An announcement from Inmune Bio ( ($INMB) ) is now available. On June 23, 2026, INmune Bio said...

3M ago

INMB

INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting

INmune Bio (INMB) announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization...

3M ago

INMB

Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan

An announcement from Inmune Bio ( ($INMB) ) is now available. At its Annual Meeting held after April...

3M ago

INMB

Maintained Buy on INmune Bio as Compelling Phase 2 Alzheimer’s Data Support XPro1595; $8 Price Target Reiterated

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Inmune Bio. The associated price target...

3M ago

INMB

0Y2 FAQ

What was Inmune Bio Inc’s price range in the past 12 months?

Inmune Bio Inc lowest stock price was €1.21 and its highest was €1.95 in the past 12 months.

What is Inmune Bio Inc’s market cap?

Inmune Bio Inc’s market cap is €58.80M.

When is Inmune Bio Inc’s upcoming earnings report date?

Inmune Bio Inc’s upcoming earnings report date is Nov 04, 2026 which is in 54 days.

How were Inmune Bio Inc’s earnings last quarter?

Inmune Bio Inc released its earnings results on Aug 06, 2026. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.179 by €0.136.

Is Inmune Bio Inc overvalued?

According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inmune Bio Inc pay dividends?

Inmune Bio Inc does not currently pay dividends.

What is Inmune Bio Inc’s EPS estimate?

Inmune Bio Inc’s EPS estimate is -0.13.

How many shares outstanding does Inmune Bio Inc have?

Inmune Bio Inc has 27,753,790 shares outstanding.

What happened to Inmune Bio Inc’s price movement after its last earnings report?

Inmune Bio Inc reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.179. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Inmune Bio Inc?

Currently, no hedge funds are holding shares in DE:0Y2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Inmune Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-26.60%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Inmune Bio Inc

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Inmune Bio (0Y2) Earnings & Revenues

Historic Earnings Reports

0Y2 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong program‑level de‑risking and tangible operational progress: formal MHRA alignment, pediatric plan approval, manufacturing readiness for Ebstracel, strengthened IP and SAB, and encouraging XPro Phase 2 imaging results with FDA Fast Track designation. Financially the quarter showed a large improvement in reported loss driven by nonrecurring items and R&D rebates, and management is controlling burn. Major near‑term milestones (UK MAA submission, EMA and US filings) are well defined. Principal concerns are a limited cash runway into Q2 2027, reliance on one‑time rebates, enrollment pace for the confirmatory trial, and financing/valuation uncertainty that could lead to dilution. On balance, the operational and clinical accomplishments outweigh the financial timing risks, but successful execution of filings and financing will be critical.View all DE:0Y2 earnings summaries

0Y2 Stock 12 Month Forecast

Average Price Target

€6.87

▲(394.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","1.75":"€1.75","3.5":"€3.5","5.25":"€5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.87278136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.87278136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.87278136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.39,1.8117524123076922,2.233504824615385,2.655257236923077,3.077009649230769,3.4987620615384616,3.920514473846154,4.342266886153846,4.764019298461538,5.185771710769231,5.6075241230769235,6.029276535384615,6.451028947692308,{"y":6.87278136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.39,1.8117524123076922,2.233504824615385,2.655257236923077,3.077009649230769,3.4987620615384616,3.920514473846154,4.342266886153846,4.764019298461538,5.185771710769231,5.6075241230769235,6.029276535384615,6.451028947692308,{"y":6.87278136,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.39,1.8117524123076922,2.233504824615385,2.655257236923077,3.077009649230769,3.4987620615384616,3.920514473846154,4.342266886153846,4.764019298461538,5.185771710769231,5.6075241230769235,6.029276535384615,6.451028947692308,{"y":6.87278136,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.569,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >